Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Get Free Report) has been given a consensus recommendation of “Hold” by the five ratings firms that are presently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $36.20.
Several brokerages have weighed in on RIGL. StockNews.com raised Rigel Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, October 18th. HC Wainwright reissued a “buy” rating and issued a $57.00 price objective on shares of Rigel Pharmaceuticals in a report on Wednesday, January 22nd. Citigroup boosted their price objective on Rigel Pharmaceuticals from $40.00 to $49.00 and gave the company a “buy” rating in a research note on Tuesday, November 12th. B. Riley increased their target price on shares of Rigel Pharmaceuticals from $17.00 to $27.00 and gave the stock a “neutral” rating in a research report on Friday, December 6th. Finally, Cantor Fitzgerald boosted their price target on shares of Rigel Pharmaceuticals from $15.00 to $25.00 and gave the company a “neutral” rating in a research report on Tuesday, December 10th.
View Our Latest Report on RIGL
Institutional Inflows and Outflows
Rigel Pharmaceuticals Price Performance
Shares of Rigel Pharmaceuticals stock opened at $22.60 on Tuesday. The firm has a market cap of $398.10 million, a PE ratio of 161.44 and a beta of 1.31. Rigel Pharmaceuticals has a 1 year low of $7.48 and a 1 year high of $29.82. The stock has a fifty day moving average price of $20.44 and a 200-day moving average price of $16.54.
Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.01 by $0.69. Rigel Pharmaceuticals had a net margin of 2.46% and a negative return on equity of 14.80%. The business had revenue of $55.31 million for the quarter, compared to analyst estimates of $40.69 million. During the same quarter in the previous year, the firm posted ($0.30) earnings per share. As a group, equities analysts anticipate that Rigel Pharmaceuticals will post 0.22 EPS for the current fiscal year.
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
See Also
- Five stocks we like better than Rigel Pharmaceuticals
- Russell 2000 Index, How Investors Use it For Profitable Trading
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- 3 Stocks to Consider Buying in October
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.